Bristol Myers Squibb: Number of Employees 2010-2022 | BMY

Interactive chart of Bristol Myers Squibb (BMY) annual worldwide employee count from 2010 to 2022.
  • Bristol Myers Squibb total number of employees in 2021 was 32,200, a 6.45% increase from 2020.
  • Bristol Myers Squibb total number of employees in 2020 was 30,250, a 0.83% increase from 2019.
  • Bristol Myers Squibb total number of employees in 2019 was 30,000, a 28.76% increase from 2018.
  • Bristol Myers Squibb total number of employees in 2018 was 23,300, a 1.69% decline from 2017.
Bristol Myers Squibb Annual Number of Employees
2021 32,200
2020 30,250
2019 30,000
2018 23,300
2017 23,700
2016 25,000
2015 25,000
2014 25,000
2013 28,000
2012 28,000
2011 27,000
2010 27,000
2009 28,000
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $161.361B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.336B 18.98
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.449B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Myovant Sciences (MYOV) United Kingdom $1.774B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.81
Zymeworks (ZYME) Canada $0.430B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.118B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00